Fanotaprim
Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor with IC50s of 1.57 and 308 nM for tgDHFR (Toxoplasma gondii DHFR) and hDHFR (human DHFR), respectively. Fanotaprim has the potential for the research of toxoplasmosis[1].
Product Specifications
CAS Number
[2120282-75-7]
Product Name Alternative
VYR-006
UNSPSC
12352005
Target
Antifolate
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/fanotaprim.html
Purity
98.89
Solubility
DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
NC1=NC=C(N2CCN(C3=CC=CC(C4=CN=C(OC)N=C4)=C3)CC2)C(N)=N1
Molecular Formula
C19H22N8O
Molecular Weight
378.43
References & Citations
[1]Hopper AT, et al. Discovery of Selective Toxoplasma gondii Dihydrofolate Reductase Inhibitors for the Treatment of Toxoplasmosis. J Med Chem. 2019;62 (3) :1562-1576.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
More Discoveries
Explore Other Products
Browse additional items from our catalog
